Truist Securities Maintains Buy Rating for ANI Pharmaceuticals: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Truist Securities has reaffirmed its Buy rating on ANI Pharmaceuticals (NASDAQ:ANIP), increasing its price target from $70.00 to $72.00. ANI Pharmaceuticals' shares have risen 5.87% in the last 24 hours to $60.93. The new price target suggests an 18.17% upside potential. ANI Pharmaceuticals focuses on developing, manufacturing, and marketing generic prescription pharmaceuticals, with the majority of its revenue coming from the United States.
February 16, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities maintains a Buy rating on ANI Pharmaceuticals, raising its price target to $72. ANIP's shares have recently increased by 5.87%, indicating positive market response.
The reaffirmation of a Buy rating and the increase in price target by Truist Securities are strong positive signals for ANI Pharmaceuticals. The recent share price increase reflects market optimism, potentially leading to further short-term gains as the new price target suggests significant upside potential.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100